Yhdysvallat - englanti - NLM (National Library of Medicine)

tersera therapeutics llc - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. in controlled studies of patients with advanced prostatic cancer comparing zoladex 3.6 mg to orchiectomy, the long-term endocrine responses and objective responses were similar between the two treatment arms. additionally, duration of survival was similar between the two treatment arms in a major comparative trial. in controlled studies of patients with advanced prostatic cancer, zoladex 10.8 mg implant produced pharmacodynamically similar effect in terms of suppression of serum testosterone to that achieved with

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

b & s healthcare - goserelin acetate - implant - 3.6 milligram - gonadotropin releasing hormone analogues

Singapore - englanti - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - goserelin acetate eqv peptide - injection - 3.6 mg/syringe - goserelin acetate eqv peptide 3.6 mg/syringe

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - goserelin acetate - prolonged-release subcutaneous implant - 3.6mg

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - goserelin acetate - prolonged-release subcutaneous implant - 10.8mg

Kenia - englanti - Pharmacy and Poisons Board

astrazeneca uk ltd parklands alderley park macclesfield cheshire - goserelin acetate - implant in pre-filled syringe - 3.6 mg goserelin acetate per depot - hormones and related agents:

Kenia - englanti - Pharmacy and Poisons Board

astrazeneca uk ltd parklands alderley park macclesfield cheshire - goserelin acetate - implant in pre-filled syringe - each injection contains 10.8 mg goserelin acetate - hormones and related agents:

Yhdysvallat - englanti - NLM (National Library of Medicine)

a-s medication solutions - goserelin acetate (unii: 6yuu2pv0u8) (goserelin - unii:0f65r8p09n) - zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b-t4 (stage b2-c) carcinoma of the prostate. treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy [see dosage and administration (2.1) and clinical studies (14.1)]. zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate [see dosage and administration (2.2) and clinical studies (14.2)]. zoladex is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months [see dosage and administration (2.3) and clinical studies (14.3)]. zoladex is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding [see dosage and administration (2.4) and cl

Australia - englanti - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - goserelin -